A landmark review has concluded that prostate cancer screening could save thousands of lives annually and should be made available to the vast majority of men. The study, conducted by esteemed scientists who analyzed data from nearly 800,000 participants, found that testing men as young as 45 for signs of prostate cancer led to fewer deaths from the disease.
Cochrane Review Findings
The Cochrane Review, a highly regarded international group of healthcare researchers, determined that prostate cancer screening is comparable to existing breast and bowel cancer screening programs. The review analyzed data from six trials dating back to 1993 and found that PSA blood tests reduced prostate cancer deaths by approximately two men per every 1,000 screened. Currently, without screening, 16 in 1,000 men die from the disease; routine screening could reduce this to 14. This means for every 500 men screened, one life is saved.
Political Support
Former Prime Minister Rishi Sunak hailed the research as a major step toward a national screening program. "As this important research shows, a targeted national screening programme for prostate cancer would save lives," Sunak said. "The Daily Mail is right that we must prevent more families from losing a father, a brother or a son to this cruel disease. So, let's take this vital step for men's health and back prostate cancer screening."
Current Screening Status
Prostate cancer is now the most common cancer in the UK, affecting one in eight men, with around 55,000 new cases and 12,000 deaths annually. Six months ago, the UK National Screening Committee (UKNSC) ruled against widespread screening on the NHS, citing the PSA test's inaccuracy and unclear impact on mortality. Instead, only men with a rare genetic mutation were eligible. However, the new Cochrane review found that offering PSA tests to men aged 45 to 85 reduced deaths by a "modest but meaningful" amount.
Expert Opinions
Dr. Phillip Dahm, a urologist from the University of Minnesota and senior author of the review, stated: "The main finding of our review is that we can now say for the first time with authority that prostate cancer screening does reduce prostate cancer mortality." He added that there is now "a reasonable evidence base to support a conversation about PSA screening." Charities believe the findings could force the UKNSC to reconsider its ruling.
Oliver Kemp, CEO of Prostate Cancer Research UK, said: "Today's Cochrane review marks an important moment in the prostate cancer screening debate. Crucially, much of the evidence underpinning these findings comes from older diagnostic pathways, where a raised PSA often led directly to biopsy and treatment. The reality today is very different. MRI, safer biopsies, active surveillance, and emerging biomarker tests now give us far better tools to reduce unnecessary biopsies, overdiagnosis, and overtreatment."
Cautions and Next Steps
Study lead author Dr. Juan Franco cautioned: "We want to be clear that this is not a blanket endorsement of universal screening. The decision should always be made between a patient and their doctor, with a full understanding of both the potential benefits and the very real risk of overdiagnosis." Researchers are currently assessing whether combining the PSA test with an MRI scan could lead to a more accurate screening program, with early research suggesting fewer harms than PSA testing alone.
A spokesperson from the Department of Health and Social Care said: "We are making progress cutting cancer waiting times and investing in research into prostate cancer detection with 227,000 more patients receiving a diagnosis for suspected cancer on time in the last 12 months alone. The UK NSC is led by science, and the committee continues to review evidence that might change screening recommendations when it becomes available."
